Article
Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell…
Lung Cancer: Targets and Therapy · 2014 · Rothschild SI
Key facts
| Title | Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence |
|---|---|
| First author | Rothschild SI |
| Journal | Lung Cancer: Targets and Therapy |
| Published | Sep 1, 2014 |
| DOI | 10.2147/LCTT.S49490 |
| Devices mentioned | K042152, K780428, K791373, K801244, K820613, K820614, K820942, K940422, K982100 |
| Product codes mentioned | CFE, CFN, DFZ, JHI, JLW |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1